Anaemias Flashcards
Sickle-cell crisis usually requires hospitalisation, (?), (?), and treatment of any concurrent infection.
Fluid replacement
Analgesia
Sickle-cell crisis usually requires hospitalisation, fluid replacement, analgesia, and treatment of any concurrent (?).
infection
In patients with sickle cell, what can be given to reduce the risk of infection? (4)
Pneumococcal vaccine
Haemophilus influenzae type b vaccine
Annual influenza vaccine
Lifelong prophylactic penicillin
(hepatitis B vaccine should also be given if patient is not immune)
In most forms of sickle-cell disease, varying degrees of (?) anaemia are present which is accompanied by increased erythropoiesis; this may increase folate requirements and supplementation with folic acid is recommended.
haemolytic
In most forms of sickle-cell disease, varying degrees of haemolytic anaemia are present which is accompanied by increased (?); this may increase folate requirements and supplementation with folic acid is recommended.
erythropoiesis
In most forms of sickle-cell disease, varying degrees of haemolytic anaemia are present which is accompanied by increased erythropoiesis; this may increase (1?) requirements and supplementation with (2?) is recommended.
- folate
2. folic acid
What drug can prevent acute chest syndrome, reduce the frequency of painful crises, and reduce transfusion requirements in sickle-cell disease?
Hydroxycarbamide
How long does it take for the benefits of hydroxycarbamide in a sickle cell patient to become evident?
Several months
Hydroxycarbamide can prevent acute chest syndrome, reduce the frequency of painful crises, and reduce transfusion requirements in sickle-cell disease.
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is common in individuals originating from (?), (?), the (?) region, and the (?)
Africa
Asia
Mediterranean
Middle East
Is G6PD more common in males or females?
Males
Individuals with G6PD deficiency are susceptible to developing (?) anaemia when they take a number of common drugs or when they have an infection.
acute haemolytic
What food can cause an acute haemolytic anaemia in patients with G6PD deficiency?
Fava beans (broad beans)
This is termed favism
G6PD deficiency is genetically (?); susceptibility to the haemolytic risk from drugs varies; thus, a drug found to be safe in some G6PD-deficient individuals may not be equally safe in others
heterogeneous
Do manufacturers routinely test drugs for their effects in G6PD-deficient inidividuals?
NO
The risk and severity of haemolysis is almost always (?)-related.
dose-related
Which drugs have a DEFINITE risk of haemolysis in most G6PD-deficient individuals? (8)
- Dapsone and other sulfones
- Fluoroquinolones (including ciprofloxacin, moxifloxacin, norfloxacin, and ofloxacin)
- Methylthionium chloride
- Nitrofurantoin
- Primaquine
- Quinolones
- Rasburicase
- Sulfonamides (including co-trimoxazole)
Dapsone has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Fluoroquinolones have a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Ciprofloxacin has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Moxifloxacin has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Norfloxacin has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Ofloxacin has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Methylthioninium chloride has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Nitrofurantoin has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Primaquine has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Quinolones have a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Rasburicase has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Sulfonamides have a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Co-trimoxazole has a definite risk of (?) in most G6PD-deficient individuals
haemolysis
Dapsone has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Fluoroquinolones have a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Ciprofloxacin has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Moxifloxacin has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Norfloxacin has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Methylthioninium chloride has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Nitrofurantoin has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Primaquine has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Quinolones have a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Rasburicase has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Sulfonamides have a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Co-trimoxazole has a definite risk of haemolysis in most (?) individuals
G6PD-deficient
Which drugs have a POSSIBLE risk of haemolysis in some G6PD-deficient individuals? (5)
Aspirin Chloroquine Menadione Quinine Sulfonylureas
(?) in mothballs also causes haemolysis in individuals with G6PD deficiency.
Naphthalene
Intravenous horse (?) globulin in combination with ciclosporin, may be used as immunosuppressive treatment for aplastic anaemia
antithymocyte
Intravenous horse antithymocyte globulin in combination with (?), may be used as immunosuppressive treatment for aplastic anaemia
ciclosporin
Intravenous horse antithymocyte globulin in combination with ciclosporin, may be used as immunosuppressive treatment for (?) anaemia
aplastic
What drug can be used for the prevention of adverse effects associated with antithymocyte globulin treatment in aplastic anaemia?
Prednisolone
Intravenous horse antithymocyte globulin in combination with ciclosporin, may be used as immunosuppressive treatment for aplastic anaemia
What drug is licensed for the treatment of idiopathic sideroblastic anaemia?
Pyridoxine hydrochloride
The dose required is usually high
(?) (recombinant human erythropoietins) are used to treat anaemia associated with erythropoietin deficiency in chronic renal failure
Epoetins
Epoetins (recombinant human erythropoietins) are used to treat anaemia associated with erythropoietin deficiency in (?)
chronic renal failure
(?) is also licensed for the prevention of anaemia in preterm neonates of low birth-weight
Epoetin beta
A therapeutic response may take several weeks
Epoetin beta is also licensed for the prevention of anaemia in (?) neonates of low birth-weight
preterm
Epoetin beta is also licensed for the prevention of anaemia in preterm neonates of (?)
low-birth weight
What hyperglycosylated derivative of epoetin has a longer-half life and can be administered less frequently than epoetin?
Darbepoetin alfa
Darbepoetin alfa is a hyperglycosylated derivative of epoetin; it has a (?) half-life and can be administered less frequently than epoetin.
longer
Darbepoetin alfa is a hyperglycosylated derivative of epoetin; it has a longer half-life and can be administered (?) frequently than epoetin.
less
(?) is a hyperglycosylated derivative of epoetin; it has a longer half-life and can be administered less frequently than epoetin.
Darbepoetin alfa
Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic (?) associated with chronic kidney disease.
anaemia
Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic anaemia associated with (?).
chronic kidney disease
Methoxy polyethylene glycol-epoetin beta has a (?) duration of action than epoetin?
longer
What very rare but severe cutaneous side effects are associated with epoetins?
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of (1?) and serious (2?) events, and in patients with cancer may increase the risk of thrombosis and related complications
- death
2. cardiovascular
Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of (?) and related complications
thrombosis
In patients being treated with erythropietins, haemoglobin concentration should be maintained within the range (?)g/100 mL
10-12 g/100mL
What are the contraindications to treat a patient with epoetins? (3)
Patients unable to receive thromboprophylaxis
Pure red cell aplasia following erythropoietin therapy
Uncontrolled hypertension
What are the common side effects of epoetins? (7)
Arthralgia Embolism and thrombosis Headache Hypertension (dose-dependent) Influenza-like illness Skin reactions Stroke
In isolated patients with normal or low blood pressure, a hypertensive crisis with (?)-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occurred with epoetin.
encephalopathy
In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and (?) requiring immediate medical attention has occurred with epoetin.
generalised tonic-clonic seizures
What needs to be monitored in patients taking epoetins?
BP
Reticulocyte counts
Haemoglobin
Electrolytes